18 June 2015 in Pediatric Hematology and Oncology
Initial Management of Childhood Acute Immune Thrombocytopenia: Single-Center Experience of 32 Years. . ???aop.label???. doi: 10.3109/08880018.2015.1040931
19 May 2002 in Medical and Pediatric Oncology
28 April 2025 in Oriental Journal of Chemistry
Crocus sativus L., known as saffron, is a plant of great medicinal, commercial and historical importance, which has been used for various purposes from ancient times to the present day. Saffron, which is often used to add flavor and color to dishes, is one of the most expensive spices in the world, which is quite difficult to cultivate due to the use of only dried stigma parts. Nowadays, with the increasing number of effective applications of saffron in the medical field and alternative medicine, it is of interest to many researchers. Saffron has many beneficial effects such as supporting digestion, pain relieving properties, calming effects, being good for insomnia, strengthening memory and increasing concentration. In addition, experiments on laboratory animals show that saffron can also be effective on cancer treatment. Therefore, as a result of extensive research on saffron, it is possible to expand the use of saffron in modern medicine. With a better understanding of the potential health benefits of saffron and the promotion of its proper use, the saffron plant could become an important source in the medical field in the future.
1 November 2008 in Pediatric Blood & Cancer
16 November 2005 in Blood
Approximately 25–30 % of children newly diagnosed with acute lymphoblastic leukemia (ALL) will eventually experience leukemic relapse. Bone marrow is the most common site of recurrence. Usually achieving a durable second remission is complicated by toxicity and resistance of the disease. Here we documented our patients in order to see the prognosis of relapsed pediatric ALL cases. RESULTS. From August 1990 to August 2005 children diagnosed with ALL and treated with BFM based protocols in Cerrahpasa Medical Faculty Pediatric Hematology-Oncology Department were enrolled to this study. There were 225 children aged median 6 years( 3 months–18 years) (136 boys/89 girls), 28 % SR, 50 % MR, 22 % HR. The whole group EFS is 72,6 % and RFI 81,8 %. Twenty-nine (12,8 %) patients were relapsed. Bone marrow recurrences were isolated in 19 patients, and combined with an extramedullary site in 8 patients (4 CNS, 2 testis, 1 retinal,1 dermal). Only two patients had isolated extramedullary site (testis) relapse. The median time to recurrence was 23 months (range 4–128 months). Five patients refused a secondary treatment. Of 24 chemotherapy given patients, 6 patients were lost just after induction therapy due to toxicity before a reliable remission evaluation was done. In three early relapses a second remission could not be attained. Twenty-one patients (72.4 %) achieved a second remission (median length, 4 months; range, 1–114 months)( mean16 ± 80 months). The 5-year survival probability among all patients was 27.2 % ± 8.2 %. Of 8 surviving patients, 3 are in remission more than 5 years, 3 are in remission 2–5 years of period and only 2 less than 1 year. One patient who relapsed for second time is in 3th remission for 65 months period. Bone marrow transplantation was the done for only 3 patients, one is very newly done, the other two relapsed after engrafmant and were lost. CONCLUSIONS. Despite acceptable long-term second EFS rates for a minor group of patients, childhood ALL recurrences signal a poor outcome being the problem of childhood ALL therapy.